A Phase 2, proof-of-concept trial of SAGE-547 for Major Depressive Disorder (MDD)

Trial Profile

A Phase 2, proof-of-concept trial of SAGE-547 for Major Depressive Disorder (MDD)

Planning
Phase of Trial: Phase II

Latest Information Update: 02 Sep 2016

At a glance

  • Drugs Brexanolone (Primary)
  • Indications Depressive disorders
  • Focus Proof of concept; Therapeutic Use
  • Most Recent Events

    • 02 Sep 2016 New trial record
    • 09 Aug 2016 According to a SAGE Therapeutics media release, top-line results are expected in the first half of 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top